Good morning you all longs... A little visit do
Post# of 155361
(Total Views: 619)
Posted On: 10/29/2023 2:29:37 AM
Good morning you all longs...
A little visit down memory street.
A recent publication "Long COVID-19 Symptoms Remedied by Anti-Viral Treatment in Neurosurgical Patients" presents a limited study in which Acyclovir (ACV) resolves different long-covid related injuries.
https://thescipub.com/abstract/ajidsp.2023.39.44
In studying the mechanism of action of ACV in "Exploiting the Anti-HIV-1 Activity of Acyclovir: Suppression of Primary and Drug-Resistant HIV Isolates and Potentiation of the Activity by Ribavirin"
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346610/
I found ... guess what ???
So, once again, there is a link between a feasible treatment to Long-Covid and CCR-5 related suppression. If we could only get our act together and do a clinical trial, we would find out what others are finding out, luckily just now in exploratory stage.
We have a drug, it works, we just need to demonstrate it.
Good rest of weekend to you all.
A little visit down memory street.
A recent publication "Long COVID-19 Symptoms Remedied by Anti-Viral Treatment in Neurosurgical Patients" presents a limited study in which Acyclovir (ACV) resolves different long-covid related injuries.
https://thescipub.com/abstract/ajidsp.2023.39.44
Quote:
This study presents case studies of long COVID-19 patients whose symptoms resolved with the chronic use of acyclovir. A novel explanation of the mechanism of symptom resolution is presented. It is the hope other researchers will contribute to this observation.
In studying the mechanism of action of ACV in "Exploiting the Anti-HIV-1 Activity of Acyclovir: Suppression of Primary and Drug-Resistant HIV Isolates and Potentiation of the Activity by Ribavirin"
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346610/
I found ... guess what ???
Quote:
RESULTS
ACV suppresses replication of primary HIV-1 isolates. Previously, we reported that ACV suppresses replication of four laboratory HIV-1 strains, CXCR4-tropic LAI.04 (HIV-1LAI.04), CCR5-tropic BaL, SF162, and AD8, in ex vivo infected human lymphoid tissues (21). Here, we evaluated the susceptibility of four primary isolates to ACV: HIV-196USNG31 and HIV-197USNG30 of clade C, HIV-196USNN20 of clade A, and HIV-1ME1 of clade B. Isolate HIV-196USNG31 uses CCR3, CCR5 , and CXCR4; HIV-196USNN20 has a broad coreceptor utilization, including CCR2B, CCR3, CCR4, CCR5 , CXCR4, Bob, and Bonzo; HIV-197USNG30 and HIV-1ME1 are exclusively CCR5 tropic.
So, once again, there is a link between a feasible treatment to Long-Covid and CCR-5 related suppression. If we could only get our act together and do a clinical trial, we would find out what others are finding out, luckily just now in exploratory stage.
We have a drug, it works, we just need to demonstrate it.
Good rest of weekend to you all.
(16)
(0)